Skip main navigation

Anti-inflammatory drug effects in IBD

Using our IBD organoculture model, we can investigate the anti-inflammatory effects of your test drugs to treat Crohn's disease or ulcerative colitis. As inflammation is a defining feature of IBD, the tissue resections (ileum or colon) are received residual to surgery with inflamed areas of the intestine determined by a pathologist.

All tissues are rapidly transported to Reprocell as fresh living tissues 24/7 for processing at our laboratories in the USA or UK.  Similar experiments can be conducted in non-human preclinical models of IBD to allow cross-species comparisons. The resultant organocultures can be exposed to a range of test agents for up to 24 hours:

  • More than 40 inflammatory mediators can be measured
  • Data from healthy, Crohn’s, and ulcerative colitis patients can be compared
  • Cross-species comparison studies, e.g. with other preclinical models of IBD
  • Tissue cytokine profiles correlate well with literature from clinical studies
  • End-point analysis includes multiplex ELISA/Luminex assay,  gene expression (RT-PCR), or immunohistochemistry (IHC)

Image: Top, A fresh gut explant from an IBD patient. Bottom, End-point analysis being performed in our Glasgow laboratory.

IBD tissue

inflammatory-bowel-disease

IBD culture study in Crohn’s or ulcerative colitis
This assay uses gut biopsies from IBD donors to assess the anti-inflammatory effects of your test articles.